Antineoplastic and Immunosuppressive Agents

1. Antimetabolites

   1. Purine Arabinosides, Xylosides, and Lyxosides

      • G. A. LePage

      Pages 426-433

   2. Antibiotics Resembling Adenosine: Tubercidin, Toyocamycin, Sangivamycin, Formycin, Psicofuranine, and Decoyinine

      • Charles A. Nichol

      Pages 434-457

   3. 8-Azaguanine

      • R. E. Parks Jr., K. C. Agarwal

      Pages 458-467

   4. Folate Antagonists

      • Joseph R. Bertino

      Pages 468-483

   5. Glutamine Antagonists

      • L. L. Bennett Jr.

      Pages 484-511

   6. Cytotoxic Amino Acid Analogs

      • Paul F. Kruse Jr.

      Pages 512-538

   7. Cytotoxic Analogs of Pyridine Nucleotide Coenzymes

      • L. S. Dietrich

      Pages 539-543

   8. Triazenoimidazole Derivatives

      • Ti Li Loo

      Pages 544-553

2. Additional Cytotoxic Agents

   1. Cytotoxic Inhibitors of Protein Synthesis

      • Arthur P. Grollman

      Pages 554-570

   2. Selective Interruption of RNA Metabolism by Chemotherapeutic Agents

      • Herbert T. Abelson, Sheldon Penman

      Pages 571-581

   3. Actinomycin D

      • Irving H. Goldberg

      Pages 582-592

   4. Daunomycin (Daunorubicin) and Adriamycin

      • A. DiMarco

      Pages 593-614

   5. Chromomycin, Olivomycin, Mithramycin

      • G. F. Gause

      Pages 615-622

   6. Nogalamycin

      • B. K. Bhuyan, C. G. Smith

      Pages 623-632

   7. Streptonigrin

      • William B. Kremer, John Laszlo

      Pages 633-641

   8. Anthramycin

      • Susan B. Horwitz

      Pages 642-648

   9. Camptothecin

      • Susan B. Horwitz

      Pages 649-656

   10. 3’-Deoxyadenosine and Other Polynucleotide Chain Terminators

       • Sune Frederiksen, Hans Klenow

       Pages 657-668

   11. Vinca Alkaloids and Colchicine

       • William A. Creasey

       Pages 686-694

   12. L-Asparaginase: Basic Aspects

       • M. K. Patterson Jr.

       Pages 712-722

Over the past two decades a number of attempts have been made, with varying degrees of success, to collect in a single treatise available information on the basic and applied pharmacology and biochemical mechanism of action of antineoplastic and immunosuppressive agents. The logarithmic growth of knowledge in this field has made it progressively more difficult to do justice to all aspects of this topic, and it is possible that the present handbook, more than four years in preparation, may be the last attempt to survey in a single volume the entire field of drugs employed in cancer chemotherapy and immunosuppression. Even in the present instance, it has proved necessary for practical reasons to publish the material in two parts, although the plan of the work constitutes, at least in the editors' view, a single integrated treatment of this research area. A number of factors have contributed to the continuous expansion of research in the areas of cancer chemotherapy and immunosuppression. Active compounds have been emerging at ever-increasing rates from experimental tumor screening systems maintained by a variety of private and governmental laboratories through­ out the world. At the molecular level, knowledge of the modes of action of established agents has continued to expand, and has permitted rational drug design to play a significantly greater role in a process which, in its early years, depended almost completely upon empirical and fortuitous observations.

• cancer
• chemotherapy
• drug
• immunosuppression
• pharmacology
• research

• Department of Pharmacology, Yale University School of Medicine, New Haven, USA

  Alan C. Sartorelli

• Laboratory of Chemical Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, USA

  David G. Johns

Policies and ethics